GeneCentric Therapeutics Announces Publication of New Results Showing Clinical Benefit of RNA-based Antifolate Predictive Response Signature (AF-PRS) to Guide Lung Cancer Treatment Selection

GeneCentric Therapeutics, a company specializing in RNA-based diagnostics for precision medicine, has recently published new findings from the Piedmont study. This study utilized real-world data to identify predictive biomarkers for approved first-line treatments in non-small cell lung cancer (NSCLC). The results highlight the clinical benefit of GeneCentric's RNA-based Antifolate Predictive Res..